Dr Reddy's CEO Expects Healthy Performance After Resolving Semaglutide Pipeline Issues

Guidance·1 article across 1 outlet

Story updated Jul 30, 2:24 AM ETRewritten when the story materially grows; the wire is checked every 15 minutesAbout this data

RDY

Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide will be ultra-competitive, with more than 20 companies trying to gain market share.

Dr Reddy's

Sources

Every quote below is verbatim from the article it is attributed to.

SourceReports the news

“Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue.”
Bloomberg — Dr Reddy's CEO On Clogged Semaglutide Pipeline